Open Access Open Access  Restricted Access Subscription Access

Misoprostol – Drug That Changed the Practice of Gynecology and Obstetrics with Its Off-Label Indications

Dr. Sushil Kumar, Dr. Kalpana Gupta, Dr. Shanmukha Sowmya Jampani


Misoprostol is a synthetic analogue of prostaglandin E1. The drug was developed by G. D. Searle & Company in 1973 for prevention of stomach ulcers. Since 1986, it is being used for its ‘off label’ indications in obstetrics and gynecology. [1] The common indications are medical termination of pregnancy (MTP), medical management of incomplete abortion, induction of labor, cervical ripening before surgical procedures and prevention and treatment of postpartum hemorrhage [2]. Since it is inexpensive, heat stable, no drug interactions and wide range of applications in reproductive health, ‘WHO’ in 2011 has added it in the model list of essential medicines. In this article we have reviewed misoprostol its uses and recommendations in modern obstetrics and gynecology.

Full Text:



Rebecca Allen & Barbara M O’Brien. Uses of Misoprostol in Obstetrics and Gynecology. Rev Obstet Gynecol. 2009 Summer; 2(3): PP. 159–168. PMCID: PMC2760893, PMID: 19826573.

Goldberg AB, Greenberg MB & Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001; 344: pp. 38–47.

Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med. 1993; 119: pp. 257–62.

ACOG Committee Opinion, authors. Number 283, May 2003. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy. Obstet Gynecol. 2003; 101: pp. 1049–1050.

L.S. & Peroff P. Amwell WR. Prostaglandins in reproductive physiology. Am J Obstet Gynecol. 1970; 7(7).

Compound Summary for Misoprostol

Robert A, Nezamis JE & Phillips JP. Inhibition of gastric secretion by prostaglandins. Am J Dig Dis. 1967 Oct; 12(10): pp. 1073–1076,

Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-efects. O.S. Tang, K. Gemzell-Danielsson, P.C. Ho. International Journal of Gynecology and Obstetrics. (2007)99: S160-S167.

Fiala C & Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception Journal. 2006-July; 74: pp. 66–86.

Orioli IM & Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG. 2000; 107: pp. 519–523.

Yedlinsky NT, Morgan FC & Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol. 2005; 105: pp. 1203–1205.

Pastuszak AL, Schüler L, Speck-Martins CE, et al. Use of misoprostol during pregnancy and Möbius’ syndrome in infants. N Engl J Med. 1998; 338: pp. 1881–1885.

Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol. 2004; 191: pp. 2168–2173.

Hale TW. Medications and Mothers’ Milk. 11th ed. Amarillo, TX: Pharmasoft Publishing; 2004.

National Abortion Federation (NAF), authors NAF Protocol for Mifepristone/Misoprostol in Early Abortion. Washington, DC: National Abortion Federation; 2008. [Accessed January 15, 2009].

Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.Obstet Gynecol. 2008; 112: pp. 1303–1310.

Henderson JT, Hwang AC, Harper CC & Stewart FH. Safety of mifepristone abortions in clinical use. Contraception. 2005; 72: pp. 175–178.

Moreno-Ruiz NL, Borgatta L, Yanow S, et al. Alternatives to mifepristone for early medical abortion. Int J Gynaecol Obstet. 2007; 96: pp. 212–218.

FIGO misoprostol-only recommended regimens 2017.

Vineeta M, Sushil Kumar, Anthony ZK et al. Vaginal misoprostol for first trimester pregnancy termination. Obstet Gynecol India. July/August 2005; 55(4).

Misoprostol for termination of second trimester pregnancy, Sarada Duwal Shrestha, Alka Singh et al. Journal of Patan Academy of Health Sciences. 2014 Jun; 1(1): pp. 16-19.

Misoprostol for intrauterine fetal death, R. Gomez Ponce de Leon, D. Wing, C.Fiala, IJGO 200: 99: S190-S19.

Bhattacharjee N, Ganguly RP & Saha SP. Misoprostol for termination of mid-trimester post-Caesarean pregnancy. Aust N Z J Obstet Gynaecol. 2007; 47: pp. 23–25.

Kruse B, Poppema S, Creinin MD & Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol. 2000; 183(2 suppl): pp. S65–S75.

National Abortion Federation (NAF), authors NAF Protocol for Mifepristone/Misoprostol in Early Abortion. Washington, DC: National Abortion Federation; 2008. [Accessed January 15, 2009].

Surg Cdr Sushil Kumar, Surg Cmde RT Awasthi & Surg Lt Cdr A Kapur. Surg Lt Cdr S Srinivas, Dr Hetal Parikh, Dr Shobha Sarkar, Induction of labour with misoprostol – A prostaglandin E1 analogue. MJAFI. 2001; 57: pp. 107–109.


  • There are currently no refbacks.